RT Journal Article SR Electronic T1 Association between the Mediterranean diet and prostate cancer risk in a Greek population JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.08.13.20172999 DO 10.1101/2020.08.13.20172999 A1 Alexandros Vaioulis A1 Kiouvrekis Yiannis A1 Konstantinos Perivoliotis A1 Gravas Stavros A1 Tzortzis Vasilios A1 Karatzas Anastasios YR 2020 UL http://medrxiv.org/content/early/2020/08/14/2020.08.13.20172999.abstract AB Purpose Dietary modifications have been correlated with survival in several neoplasia, such as prostate cancer. The present study was designed to investigate the association between the Mediterranean diet and prostate cancer risk.Methods A retrospective analysis of patients with a high suspicion of suffering from prostate cancer (PCa) who underwent prostate biopsy was performed. According to histopathology, two groups were generated, the PCa group and the Healthy group. The dietary profile of our study population was implemented, based on a modified MDS (Mediterranean Diet Score) questionnaire. A logistic regression model was used for the interpretation of our data.Results In total, 431 patients with prostate cancer and 279 healthy men were included in our study. The demographic characteristics of the patients were comparable. Daily consumption of white meat (OR: 0.59), dairy products (OR: 0.64), nuts (OR: 0.63) and whole grains (OR: 0.55) was higher in healthy males. Infrequent consumption of vegetables was linked with an increased rate of PCa (OR: 2.55). Interestingly daily consumption of processed meat rates was higher in healthy men. However, a significant correlation between specific intake products or frequency and the incidence of PCa was not established.Conclusions Although, an association between the dietary patterns and PCa was not determined, components consumption patterns displayed a higher daily intake rate of white meat, dairy products, nuts and whole grains. Further prospective trials are required to validate the effect of Mediterranean diet in the incidence and mortality of PCa patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the Ethics Committee of the University Hospital of Larissa, GreeceAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available by the last author